US FDA Panel Says Amgen Lung Cancer Drug Data Cannot Be Relied On

October 6, 2023

(Reuters) – Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial of Amgen’s Lumakras could not be relied on, raising questions about the agency’s upcoming decision on whether to grant traditional approval of the drug for a type of advanced lung cancer. The drug was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data a condition for gaining traditional approval. (Read More)